Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is targeting the next wave of DNA damage response (DDR) cancer therapies, as highlighted in a recent BioMedWire editorial. The company is advancing ONC010, a nanoparticle-encapsulated inhibitor of polynucleotide kinase/phosphatase (PNKP), an enzyme involved in multiple DNA repair pathways. This approach aims to address cancers that are resistant to current treatments, including PARP inhibitors.
The editorial notes that the DDR inhibitor market is rapidly expanding, with new drug classes emerging beyond PARP inhibitors. Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology, positioning it as an early leader in this novel class of cancer therapeutics. Preclinical data presented by the company showed that ONC010 more than doubled median survival in PTEN-deficient colorectal cancer animal models while demonstrating a favorable toxicity profile.
Onco-Innovations is progressing ONC010 through manufacturing scale-up and IND-enabling studies, with plans for first-in-human clinical development. The company’s efforts are supported by its proprietary SynoGraph causal AI platform through subsidiary Inka Health. The editorial also reviewed recent developments in oncology and biotechnology involving AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD), and Foghorn Therapeutics Inc. (NASDAQ: FHTX).
The full press release can be viewed at https://ibn.fm/HH1VP. Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company has secured an exclusive worldwide license to patented technology that targets solid tumors.
The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF.
